Sanofi Receivables 2010-2024 | SNY
Sanofi receivables from 2010 to 2024. Receivables can be defined as the total amount of collectibles for a company
- Sanofi receivables for the quarter ending December 31, 2024 were $9.091B, a 4.81% decline year-over-year.
- Sanofi receivables for 2024 were $9.091B, a 4.81% decline from 2023.
- Sanofi receivables for 2023 were $9.55B, a 3.03% increase from 2022.
- Sanofi receivables for 2022 were $9.27B, a 4.22% decline from 2021.
Sanofi Annual Receivables
(Millions of US $) |
| 2024 |
$9,091 |
| 2023 |
$9,550 |
| 2022 |
$9,270 |
| 2021 |
$9,678 |
| 2020 |
$8,557 |
| 2019 |
$8,889 |
| 2018 |
$8,574 |
| 2017 |
$8,156 |
| 2016 |
$8,090 |
| 2015 |
$8,201 |
| 2014 |
$9,503 |
| 2013 |
$9,074 |
| 2012 |
$9,655 |
| 2011 |
$11,201 |
| 2010 |
$8,641 |
| 2009 |
$8,389 |
Sanofi Quarterly Receivables
(Millions of US $) |
| 2024-12-31 |
$9,091 |
| 2024-09-30 |
|
| 2024-06-30 |
$9,482 |
| 2024-03-31 |
|
| 2023-12-31 |
$9,550 |
| 2023-09-30 |
|
| 2023-06-30 |
$9,423 |
| 2023-03-31 |
|
| 2022-12-31 |
$9,270 |
| 2022-09-30 |
|
| 2022-06-30 |
$573 |
| 2022-03-31 |
|
| 2021-09-30 |
|
| 2021-03-31 |
|
| 2020-09-30 |
|
| 2020-03-31 |
|
| 2019-09-30 |
|
| 2019-03-31 |
|
| 2018-03-31 |
|
| 2017-12-31 |
$8,156 |
| 2017-09-30 |
|
| 2017-06-30 |
$7,544 |
| 2017-03-31 |
|
| 2016-12-31 |
$8,090 |
| 2016-09-30 |
|
| 2016-06-30 |
$8,235 |
| 2016-03-31 |
|
| 2015-09-30 |
|
| 2015-06-30 |
$8,590 |
| 2014-06-30 |
$9,791 |
| 2013-06-30 |
$9,943 |
| 2012-06-30 |
$10,530 |
| 2012-03-31 |
|
| 2011-12-31 |
$11,201 |
| 2011-09-30 |
|
| 2011-06-30 |
$11,092 |
| 2011-03-31 |
|
| 2010-12-31 |
$8,641 |
| 2010-09-30 |
|
| 2010-06-30 |
$8,915 |
| 2010-03-31 |
|
| 2009-12-31 |
$8,389 |
| 2009-09-30 |
|
| 2009-06-30 |
$7,994 |
| 2009-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$136.409B |
$44.458B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
